UnknownNot Applicable

Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System

China150 participantsStarted 2022-08-01

Plain-language summary

The OLGIM staging system is highly recommended for a comprehensive assessment of GIM severity to evaluate patients' gastric cancer risk. However, its need to take at least 4 biopsies is not clinically feasible due to a serious shortage of pathologists compared with the large number of gastric cancer screening population. We plan to develop a Digital Pathology artificial intelligence diagnosis system (DPAIDS), to automatically identify tumor areas in whole slide images(WSI) and quickly and accurately quantify the severity of intestinal metaplasia according to the proportion of intestinal metaplasia areas.

Who can participate

Age range40 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients aged 40-75 years who undergo the gastroscopy examination and biopsy Exclusion Criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy * patients with previous surgical procedures on the stomach * patients with contraindications to biopsy * patients who refuse to sign the informed consent form

What they're measuring

The diagnostic performance of AI model to assess the severity of intestinal metaplasia

Timeframe: 2 years

Trial details

NCT IDNCT05447221

SponsorShandong University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-31

Contact for this trial

Yanqing Li, MD, PhD

0531182169385 liyanqing@sdu.edu.cn

View on ClinicalTrials.gov More Gastric Intestinal Metaplasia trials